Charcot-Marie-Tooth disease type 4F

Charcot-Marie-Tooth disease type 4F (CMT4F), also known as Charcot-Marie-Tooth disease type 4F or CMT4F, is a rare autosomal recessive demyelinating peripheral neuropathy caused by mutations in the PRX gene (periaxin), which encodes a protein essential for the maintenance of peripheral nerve myelin sheaths. The disease belongs to the broader group of hereditary motor and sensory neuropathies (HMSN) and specifically falls within the CMT4 subgroup of demyelinating forms with recessive inheritance. CMT4F primarily affects the peripheral nervous system, leading to progressive weakness and atrophy of the distal muscles of the limbs, particularly the feet and hands. Key clinical features include early-onset distal muscle weakness, foot deformities (such as pes cavus or pes planus), difficulty walking, sensory loss in the extremities, reduced or absent deep tendon reflexes, and markedly reduced nerve conduction velocities consistent with demyelination. Some patients may also develop scoliosis. The severity can vary, but many patients experience significant motor disability, and some may require assistive devices for ambulation. Onset is typically in childhood, though the age at which symptoms become apparent can vary. There is currently no cure for CMT4F. Treatment is supportive and symptomatic, focusing on physical therapy and rehabilitation to maintain muscle strength and mobility, orthopedic interventions such as braces or corrective surgery for foot deformities, occupational therapy for hand function, and pain management when needed. Regular monitoring by a multidisciplinary team including neurologists, orthopedic specialists, and rehabilitation professionals is recommended to optimize quality of life and functional outcomes.

Common questions about Charcot-Marie-Tooth disease type 4F